<DOC>
	<DOCNO>NCT00927082</DOCNO>
	<brief_summary>This study long-term post-treatment follow-up study WV19432 , evaluate efficacy safety PEGASYS patient HBeAg positive chronic hepatitis B ( CHB ) .Patients receive treatment PEGASYS , complete follow-up , eligible enter post-treatment follow-up study . The anticipated time study 5 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Follow-Up Study WV19432 , Evaluate Long Term Post-Treatment Effects PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Patients With HBeAg Positive Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Informed consent Study WV19432 Patients complete treatment followup study WV19432 As Study WV19432</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>